RTP Mobile Logo
Dermatologic Oncology Update, Issue 1, 2011
Released July 2011

Featuring interviews with Drs Keith T Flaherty, Jedd D Wolchok and Aleksandar Sekulic. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Taken together, melanoma and nonmelanoma skin cancer — basal cell and cutaneous squamous cell cancer (BCC and SCC) — likely represent the most prevalent form of human cancer. Fortunately, the vast majority of skin cancers present as minimally invasive BCC and SCC and, as such, are highly curable with local treatment alone. However, in rare instances, these characteristically indolent lesions progress and necessitate systemic intervention with the support of limited randomized clinical evidence. In contrast, malignant melanoma is the most aggressive form of skin cancer with a predilection toward distant metastases, even when identified in the clinically early stages of disease. Thus melanoma and nonmelanoma skin cancer are distinct entities, each posing unique challenges to the oncology community. Featuring information on the latest research developments along with expert perspectives, this CME activity is designed to assist medical oncologists, hematologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES
    • Integrate practice-changing clinical trial results into the evidence-based treatment algorithm for front-line and subsequent management of advanced melanoma (MSC) and nonmelanoma skin cancer (NMSC).
    • Recognize immune-related adverse events (irAEs) associated with anti-CTLA-4 antibody therapy, and offer supportive management strategies to minimize and/or manage these side effects.
    • Communicate a mechanistic understanding of the relationship between development of clinically apparent irAEs and melanoma response to ipilimumab.
    • Compare and contrast the patterns of tumor response resulting from melanoma treatment with cytotoxic versus immunotherapeutic agents.
    • Summarize the scientific rationale for the current investigation of B-raf inhibitors in melanoma.
    • Explain the fundamental role of hedgehog signaling in BCC pathogenesis and treatment.
    • Recall the design of ongoing clinical trials in advanced MSC and NMSC, and consent or refer eligible patients for study participation.
    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY

    CME credit is no longer available for this issue

    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CONTENT VALIDATION AND DISCLOSURES


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDr Sekulic had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr FlahertyAdvisory Committee: Bristol-Myers Squibb Company, Eisai Inc, Genentech BioOncology; Consulting Agreements: Cephalon Inc, GlaxoSmithKline. Dr Wolchok Advisory Committee: Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Bristol-Myers Squibb Company, Celgene Corporation and Genentech BioOncology.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: July 2011
    Expiration date: July 2012

Acknowledge and close

Listen to audio:
Dermatologic Oncology Update, Issue 1, 2011
Released July 2011

Featuring interviews with Drs Keith T Flaherty, Jedd D Wolchok and Aleksandar Sekulic. (Text and Audio Content)

Read print: